drugset / Trial / NCT06264440

A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants

NCT06264440

Phase 1 Completed 18 enrolled Biogen
Non-randomizedCrossoverOpen-labelTreatment

Summary

The primary objective of the study is to evaluate the effects of a proton pump inhibitor (PPI) \[rabeprazole\] on BIIB122 pharmacokinetics (PK) after a single dose in healthy participants. The secondary objective of the study is to evaluate the safety and tolerability of BIIB122, with and without a PPI (rabeprazole), after a single dose in healthy participants.

Timeline

Start
2024-02-12
Primary completion
2024-06-18
Completion
2024-06-18

Drugs

EvaluationDrugModalityDoseRoute
Subject BIIB122 Small molecule Oral
Subject Rabeprazole Small molecule

Indications

No indication recorded.